FDA Approves New Treatment Option for Breast Cancer

Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just days before the start of breast cancer awareness month when it added a new molecularly targeted therapeutic to the armamentarium for oncologists treating patients with breast cancer: abemaciclib (Verzenio).

Read More

FDA Approvals for Liver and Stomach Cancer Extend the Reach of Immunotherapy

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics known as checkpoint inhibitors are a treatment option when it expanded the approved uses of nivolumab (Opdivo) and pembrolizumab (Keytruda) to include certain patients with liver cancer and stomach cancer, respectively.

Read More

FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma

The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last week with the approval of the molecularly targeted therapeutic copanlisib (Aliqopa) for the treatment of certain adults with non-Hodgkin lymphoma.

Read More

New Treatment for Adults with Acute Lymphoblastic Leukemia Approved by the FDA

This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel (Kymriah) for treating certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL) was not the only good news for ALL community in August. Earlier in the month, the FDA approved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating adults who have B-cell precursor ALL that did not respond to initial treatment or that returned after treatment.

Read More

FDA Approves Two New Treatments for Acute Myeloid Leukemia

This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists treating certain groups of patients with acute myeloid leukemia (AML): enasidenib (Idhifa) and Vyxeos. This news is particularly welcome because AML is the form of leukemia with the lowest five-year relative survival rate.

Read More

FDA Approves a New HER2-targeted Therapeutic for Breast Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx) for treating certain patients with HER2-positive breast cancer. Specifically, the FDA approved neratinib for reducing disease recurrence in patients with early-stage HER2-positive breast cancer who have completed postsurgery (adjuvant) treatment with trastuzumab (Herceptin) and whose disease has not progressed.

Read More

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More